Is the new mRNA crown vaccine coming on the domestic market? Declassified behind the China-Germany vaccine cooperation

Photo Wen/Zhang Hongtao Associate Professor, University of Pennsylvania School of Medicine Core Tips 1. The first emergency new crown vaccine in Europe and the United States, BNT162b2, is the product of global cooperation, germany, the United States, China.
based on BioNTech's proprietary mRNA vaccine technology platform, with fosun Pharma and Pfizer.
, Fosun has been deeply involved in vaccine research and development, and its bridding test data provide reference for Asian countries.
2. MRNA vaccine has the advantages of short development cycle, dual mechanism of action, no viral components and relatively simple production process.
, which focuses on and understands mRNA technology, successfully intercepted Hu Pfizer and, in partnership with BioNTech, obtained a vaccine sales trial in Greater China to develop the Chinese market.
the market for Fosun Pharma, in addition Chinese mainland, there are Hong Kong, Macao and Taiwan, and Taiwan also needs to buy through Fosun.
current drawback of the vaccine is that it requires minus 70 degrees of storage, but it is not a fatal injury.
has been building a 70C cold storage facility near the airport, and the vaccine can be placed at 2 to 8C for five days.
primary vaccination point will also be equipped with refrigerators, in terms of quantity, price and so on will not constitute an access barrier.
. The general principle of vaccine pricing is that, as a public health product, pricing must be within the reach of the general public.
provided in a near-free manner, taking into account the costs of research and development and production.
as a pharmaceutical company, we should consider both the health of the people and the interests of shareholders.
2nd, the UK approved the emergency use of the new crown mRNA vaccine BNT162b2.
11 December, the United States also approved the emergency use of the vaccine (EUA).
is the first emergency new crown vaccine in Europe and the United States.
phase III clinical trials, the vaccine showed a 95 percent protection rate.
December 16, Fosun Pharma announced the progress of its partnership with BioNTech, a German bio-technology company, on the mRNA vaccine, indicating that at least 100 million doses of BNT162b2 will be available to the mainland market after national approval.
hong Kong and has imported nearly 7.5 million doses.
China has approved the emergency use of three inactivated vaccines, and foreign media believe that China is now ready to introduce mRNA vaccines, and domestic vaccines are complementary rather than competitive.
also believe that Fosun Pharma's partnership with BioNTech is just a partnership between dealers and research and development companies, and that the development of this mRNA vaccine is basically nothing for Fosun.
As of December 19, Fosun Vaccine Phase II trials in Taizhou and Sushui, Jiangsu Province, have been completed ahead of schedule, the number of participants is 960 people, the current response is good, did not receive any serious adverse events reported.
end point of the second phase of the trial is expected to be reached in two months, and the official listing needs to be approved by the drug regulatory department.
the drug available, it will have a Chinese product name and is currently being registered.
to sort out Fosun's relationship with the mRNA vaccine and when it will be available in China? Does Fosun Pharma's rights cover hong Kong, Macao and Taiwan, in addition to mainland China? Do these regions also need to buy the vaccine from Fosun instead of Pfizer? What's the price? Recently, the author interviewed Fosun Pharma Senior Vice President, President of Global Research and Development and Chief Medical Officer, Chairman of the Scientific Committee Dr. Hui Aimin, according to the interview records, collated the writing of this article.
/Dr. Hui Aimin attended the 2020 World Dialogue Pacific Future Forum organized by Phoenix Satellite TV and Phoenix.com. Why did Fosun choose to work with an unknown German company to produce the mRNA vaccine? At the beginning of 2020, after the outbreak of the new crown in Wuhan, Fosun decided to develop the vaccine using the technical route of mRNA, which was not a decision to pat the head, but a result of the attention and understanding of mRNA technology over the past two or three years.
, Dr. Hui Aimin, said that the use of mRNA technology to make vaccines has four advantages: 1. The research and development cycle is short.
know the genetic sequence of the virus, a new candidate mRNA vaccine can be designed within days, and samples can be produced in a few weeks for animal experiments.
2. Dual mechanism.
mRNA vaccine can stimulate the body's fluid immunity and T-cell immunity, immunogenicity is strong.
, traditional vaccines mainly activate body fluid immunity, which is weak for cellular immunity.
and the mRNA vaccine does not require adulations to strengthen immunity and avoid side effects from the use of adrenasts.
3. No viral components.
mRNA vaccine uses only synthetic mRNA, a protein that encodes the virus, no ingredients that come directly from the virus, and no security risks from the virus.
. The production process is relatively simple.
although mRNA vaccines are highly technical and technically available, once put into production, the process is relatively simple and easy to mass produce, making them particularly suitable for responding to vaccine shortages arising from major outbreaks.
because of its knowledge of mRNA technology, Fosun contacted BioNTech, which has the technology, in order to develop an mRNA vaccine.
the BioNTech vaccine was approved on December 18, U.S. Eastern Time, after BioNTech's vaccine was approved for emergency use in the United States.
talks with BioNTech went very well, and Fosun Pharma's ultimate partner, BioNTech, was chosen.
and Pfizer are partners in the BioNTech vaccine in Germany, and Fosun is responsible for the development of vaccine sales trials in Greater China.
is responsible for sales in all countries and regions outside Greater China.
, cut Hu Pfizer, preempt the cooperation with BioNTech in Germany? The two boxes of rice created an opportunity for cooperation, $85 million of co-financing has been returned, there is no doubt that Chinese scientists announced on January 12th the new coronavirus gene, is the cornerstone of all non-traditional vaccine research can be officially carried out.
the virus's genetic sequence, nucleic acids that encode proteins can be designed and even produced directly.
new crown vaccine project for BioNTech, launched on January 27.
first telephone call with the BioNTech team on January 29th, when Dr. Hui Aimin was in Boston, USA.
week later, the two sides signed a nondisclosure agreement and began formal talks on concrete cooperation.
24-hour relay with Fosun Pharma's research and development team in Boston and China, providing the first clinical development of an mRNA vaccine in China in two days.
that Germany is a country that respects efficiency, and the efficiency of Fosun's team has impressed Germany's BioNTech.
February 9, BioNTech co-founder and CEO Dr. Ugur Sahin visited Boston Lightning, Ugur's trip was only a meeting with investment tycoons, did not schedule a meeting with Fosun's team, and did not have time to discuss cooperation with Fosun.
, Dr. Hui thinks it's a very rare opportunity.
that Fosun had never had any contact with the German company until January 29th, and that although cooperation talks had begun, they were mainly conducted online and in writing.
as the saying goes, if there is no opportunity to meet and exchange, it is not conducive to the negotiations.
, Ugur's schedule is too tight to squeeze time.
can only make a trick to see stitches, suggested that Uur can get off the plane and have a light meal together to talk.
, Ugur's plane arrived at no dinner time, but agreed to meet Dr. Hui at the hotel.
, Dr. Hui asked for two simple boxes of rice for a working dinner at a restaurant near the hotel where Uur stayed.
In a sense, the boxes were wasted, and neither Ugur and Dr. Hui had much time to enjoy them, but instead grabbed every minute, asking and presenting their specifics, including research and development capabilities and clinical research plans.
a brief meeting that had not been planned and lasted more than two hours.
so, in the history of Fosun Pharma's partnership with BioNTech, these two boxes of rice should be left a legendary status.
the meeting, negotiations between the two sides moved forward quickly and a week later signed an intention to cooperate.
March 13, Fosun Pharma signed a formal cooperation agreement with BioNTech.
terms of the agreement, BioNTech will jointly develop and promote the launch of the new mRNA crown vaccine in China, utilizing Fosun Pharma's extensive clinical development, compliance registration and commercialization capabilities in China.
the partnership, Fosun Pharma will pay up to $35 million in licensing fees, including down payments, clinical development registrations and sales milestones.
same time, Fosun Industries, Fosun Pharma's controlling subsidiary, subscribed for $31.63 per share for 1,580,777 new common shares of BioNTech.
BioNTech's share price has now exceeded $100.
, Fosun Pharma's stake in BioNTech is enough to cover the costs of the contract with BioNTech.
now, Fosun Pharma's partnership with BioNTech is nothing short of a divine operation.
completed such a divine operation, from the first conference call to the formal signing, only six weeks between, and Dr. Hui and Dr. Uur two boxes of rice meeting, also became a significant offline communication between the two companies.
/BioNTech founders Uur Sahin and Zlem Türeci, an immigrant couple from Turkey, co-founded the company that was originally used to develop cancer vaccines.
on March 17, four days later, BioNTech signed a partnership agreement with Pfizer, which will be responsible for markets other than Greater China.
media have questioned why Pfizer is abandoning the Chinese market. In response, Pfizer said it did not want the Chinese market, which is already covered by BioNTech's partnership with Fosun Pharma.
Before the new crown outbreak, Pfizer and BioNTech had been working together on the flu mRNA vaccine since 2018, but as long as Pfizer started a few days earlier, Pfizer won the global market for the new crown vaccine.
so, looking back on this history, Fosun is lucky.
, however, luck is reserved for those who are prepared, without Fosun's previous focus on mRNA technology, without those two boxes of rice, perhaps this mRNA vaccine, there would be nothing about Fosun.
/BioNTech, Germany, is located in the main administrative and laboratory building in Mainz.
the collaboration between Fosun Pharma and BioNTech, Dr. Hui summed it up with "Time, Land, People, and" to sum it up.
, it was because of a sudden new crown outbreak.
because bioNTech, even with its technology, needs to conduct clinical trials in the outbreak area because of the outbreak in Wuhan at the beginning of the year, so it needs to find a partner in China.
and bioNTech learned about Fosun Pharma's social responsibility, research and development capabilities and clinical resources, and was impressed by Fosun's ability to respond quickly.
, of course, this kind of day, the land, is not what we want to see.
Fossun Pharma will be responsible for conducting clinical research on vaccines in China under the original partnership, while BioNTech retains markets outside China to promote vaccines worldwide through other partners after successful clinical studies in China.
, Fosun is ready to play clinically.
but the plan didn't change fast.
As a result of China's strong anti-epidemic measures, the new crown outbreak in China has been rigidly controlled, after March, basically only imported cases of infection, although sporadic outbreaks in some areas, but also quickly controlled, eliminated.
, the United States, Europe has the world's largest outbreak, Europe and the United States and other countries have become the main field of vaccine clinical research.
, Fosun vaccine only need to carry out the second phase of bridding trials in China? What are the side effects? When will it go on sale? In the face of the new crown outbreak, China has prepared five technical routes, including inactivated vaccines and adenovirus outbreaks, as well as nucleic acid vaccines.
to prepare a variety of technical routes at the same time.
new coronavirus is a new thing, and it is impossible to know exactly what kind of technical path will succeed.
opportunities are reserved for those who are prepared.
countries, lacking the capacity to develop vaccines, are only prepared to buy large quantities of vaccines.
canada, for example, the new crown vaccine purchase agreement, if all successful, would allow every Canadian to take an average of 10 doses.
So now that the mRNA vaccine clinical trial has been successful, Fosun Pharma is preparing to import at least 100 million doses of the vaccine under a previous cooperation agreement with a German company, which is not intended to be used as an explanation for the success of other vaccines, other than to explain the success of the vaccine.
success of the trial depends on data from Phase III clinical trials.
, Fosun is not just playing a simple importer, even though it doesn't have a home for vaccine clinical studies as wishes.
in the development of vaccines, Fosun Pharma has been deeply involved from start to finish.
, according to Dr. Hui, the German company started in the hands of the new preclinical crown vaccine candidate, in fact, there are more than 20, in the end which can finally succeed